Categories: News

LEPAS Ships LEPAS L4 to South Africa, Accelerating Global Market Expansion

TAICANG, China, Jan. 28, 2026 /PRNewswire/ — On January 26, the all-new NEV brand LEPAS completed its export shipment at Taicang Port. The first batch of over 500 LEPAS L4 vehicles was officially loaded and shipped to Durban Port, South Africa.

- Advertisement -

South Africa is one of the key hubs in Africa’s vehicle market and also one of the world’s major right-hand-drive markets. With its well-developed ports and logistics networks, the country serves as an important gateway for overseas brands expanding into Africa. The LEPAS L4 in this shipment is built on Chery Group’s all-new LEX intelligent platform, measuring 4,400 × 1,820 × 1,635 mm with a wheelbase of 2,700 mm. From the consumer perspective, the LEPAS L4 aligns with the global automotive market’s ongoing transition toward new energy, meeting potential demand for high-quality NEVs. From the brand perspective, this shipment also signifies that LEPAS’s products are fully prepared to deliver an elegant driving and handling experience for users with diverse driving habits, even under complex road conditions. By collecting real-world feedback, LEPAS will progressively refine its products and service systems, laying the groundwork for further market expansion and brand development.

- Advertisement -

Following the arrival of the first batch at Durban Port, LEPAS will use South Africa as a strategic hub to expand other markets, leveraging the country’s mature vehicle distribution system, ports, and logistics networks. While consolidating its own advantages, LEPAS will continue to implement the Group’s “In Somewhere, For Somewhere, Be Somewhere” strategy, focusing on localized operations and product innovation to deliver more intelligent and more elegant NEV mobility solutions for local consumers.

- Advertisement -

South Africa is just the starting point for LEPAS’s global expansion. The brand will continue to introduce its products, networks, brand presence, and after-sales services across countries and continents, bringing its philosophy of elegant lifestyle, supporting infrastructure, cutting-edge NEV technologies, and employment opportunities related to the new energy vehicle industry to the world, positioning itself as a long-term contributor to the global NEV mobility ecosystem.

- Advertisement -

For the latest updates, follow us on our official social media channels.

- Advertisement -

YouTube: https://youtube.com/@lepasinternational
Instagram: https://www.instagram.com/lepas.international
TikTok: https://www.tiktok.com/@lepas.international
Facebook: https://www.facebook.com/profile.php?id=61578653973934 

- Advertisement -

Photo – https://mma.prnewswire.com/media/2871690/LEPAS.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/lepas-ships-lepas-l4-to-south-africa-accelerating-global-market-expansion-302672813.html

- Advertisement -

Recent Posts

Dalton Pharma Services Expands Aseptic Powder Fill-Finish Capacity with RoboFil system in Toronto

A fully automated aseptic fill-finish platform delivers greater speed, flexibility, and quality for the manufacturing…

14 minutes ago

Deakin University advances global agenda for affordable health through RAAH Roundtable

NEW DELHI, March 31, 2026 /PRNewswire/ -- Deakin University, Australia, ranked among the top 1%…

14 minutes ago

SirPAD: Primary Results confirm the safety and efficacy of Sirolimus Coated Balloon in PAD

TAMPA, Fla., March 31, 2026 /PRNewswire/ -- Concept Medical Inc. (CMI), a global leader in…

15 minutes ago

DNV SELECTED TO CERTIFY CLASS D DEVICES FOR LEADING U.S. MANUFACTURER UNDER EU IVDR

DNV supports the manufacturer's transition to new regulation with its digital certification platform and transparent,…

15 minutes ago

BioAtla Announces Share Consolidation

March 31, 2026 16:06 ET  | Source: BioAtla, Inc. SAN DIEGO, March 31, 2026 (GLOBE…

3 hours ago

Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

– Released positive topline data from Phase 1 study of IV rademikibart in patients with…

3 hours ago